JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...

JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years -- ...

AUSTIN, TX, USA I January 30, 2025 I Gameto, a clinical-stage biotech company developing iPSC-based therapies for women’s health, today announced that the ...

MUNICH, Germany I January 30, 2025 I Tubulis announced today that its second drug candidate, TUB-030, has entered clinical evaluation with successful dosing ...

MUNICH, Germany I January 30, 2025 I Ethris GmbH, a leading biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced ...

SAN MATEO, CA, USA I January 29, 2025 I Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting ...

SOUTH SAN FRANCISCO, CA, USA I8, 2025 I Helicore Biopharma Inc., a biopharmaceutical company focused on the discovery and development of ...

PLANTATION, FL, and GAITHERSBURG, MD, USA I January 28, 2025 I miRecule, a biotechnology company pioneering RNA therapies, and GBI Biomanufacturing, a ...

PISCATAWAY, NJ, USA I January 28, 2025 I Kashiv Biosciences, LLC, a global leader in biopharmaceutical innovation, today announced that their abatacept ...

SAN FRANCISCO, CA, USA I7, 2025 I GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing ...

SOUTH SAN FRANCISCO, CA, USA I8, 2025 I Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the ...

Trial anticipated for H2 2025 to evaluate most advanced next generation intranasal pertussis vaccine for whooping cough ...